Krystal Biotech (NASDAQ:KRYS) Shares Down 3.1%

Krystal Biotech, Inc. (NASDAQ:KRYS) dropped 3.1% during mid-day trading on Tuesday . The company traded as low as $187.62 and last traded at $188.21. Approximately 100,366 shares changed hands during mid-day trading, a decline of 71% from the average daily volume of 350,665 shares. The stock had previously closed at $194.27.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on KRYS. Evercore ISI lifted their price target on shares of Krystal Biotech from $201.00 to $206.00 and gave the stock an “outperform” rating in a report on Monday, August 12th. Stifel Nicolaus increased their price target on Krystal Biotech from $204.00 to $220.00 and gave the company a “buy” rating in a research note on Wednesday, September 11th. William Blair upgraded Krystal Biotech to a “strong-buy” rating in a research report on Friday, August 30th. Citigroup reiterated a “neutral” rating and issued a $204.00 target price (up from $195.00) on shares of Krystal Biotech in a report on Tuesday, August 6th. Finally, HC Wainwright increased their target price on shares of Krystal Biotech from $200.00 to $221.00 and gave the company a “buy” rating in a research report on Wednesday, August 28th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $196.75.

Krystal Biotech Price Performance

The firm has a market capitalization of $5.40 billion, a price-to-earnings ratio of 101.21 and a beta of 0.82. The business’s fifty day simple moving average is $196.09 and its 200 day simple moving average is $178.99.

Krystal Biotech (NASDAQ:KRYS) last issued its earnings results on Monday, August 5th. The company reported $0.53 EPS for the quarter, beating the consensus estimate of $0.50 by $0.03. Krystal Biotech had a return on equity of 1.99% and a net margin of 63.73%. The company had revenue of $70.28 million during the quarter, compared to the consensus estimate of $65.27 million. During the same period last year, the business posted ($1.25) EPS. The firm’s revenue for the quarter was up 70283900.0% compared to the same quarter last year. Equities research analysts expect that Krystal Biotech, Inc. will post 3.13 earnings per share for the current fiscal year.

Insider Buying and Selling at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the transaction, the insider now directly owns 1,500,882 shares of the company’s stock, valued at approximately $296,814,424.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 14.10% of the company’s stock.

Hedge Funds Weigh In On Krystal Biotech

Several hedge funds have recently modified their holdings of the company. EFG Asset Management North America Corp. increased its position in shares of Krystal Biotech by 0.5% during the second quarter. EFG Asset Management North America Corp. now owns 12,555 shares of the company’s stock valued at $2,308,000 after acquiring an additional 60 shares during the last quarter. GAMMA Investing LLC increased its position in shares of Krystal Biotech by 160.3% during the 2nd quarter. GAMMA Investing LLC now owns 151 shares of the company’s stock valued at $28,000 after purchasing an additional 93 shares during the last quarter. Nisa Investment Advisors LLC raised its stake in shares of Krystal Biotech by 11.1% during the 2nd quarter. Nisa Investment Advisors LLC now owns 940 shares of the company’s stock worth $173,000 after purchasing an additional 94 shares during the period. Arizona State Retirement System boosted its holdings in shares of Krystal Biotech by 2.1% in the 2nd quarter. Arizona State Retirement System now owns 5,147 shares of the company’s stock worth $945,000 after buying an additional 108 shares during the last quarter. Finally, Fiera Capital Corp grew its position in Krystal Biotech by 0.8% during the second quarter. Fiera Capital Corp now owns 16,208 shares of the company’s stock valued at $2,976,000 after buying an additional 130 shares during the period. Institutional investors own 86.29% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).